History | Ustekinumab for the treatment of adults with moderate to severe psoriasis | Guidance | NICE

History

A list of downloadable documents created during development.

Background information

Review decision - September 2010 information
Appendix A: Decision paper presented to the Institute's Guidance Executive ^{PDF 105 KB} 30 September 2010
Review proposal - August 2010 information
Appendix A: provisional matrix of stakeholders ^{PDF 29 KB} 23 August 2010
Appendix B: proposal paper presented to the Institute's Guidance Executive ^{PDF 285 KB} 23 August 2010
NICE guidance recommends treatment for severe plaque psoriasis ^{PDF 70 KB} 06 December 2013

Psoriasis - ustekinumab: final appraisal determination

Psoriasis - ustekinumab: final appraisal determination information
Psoriasis - ustekinumab: final appraisal determination ^{PDF 134 KB} 14 August 2009
Response to consultee, commentator and public comments on the appraisal consultation document (ACD) ^{PDF 133 KB} 14 August 2009
Consultee and commentator comments on the ACD
Janssen-Cilag ^{PDF 86 KB} 14 August 2009
British Association of Dermatologists ^{PDF 28 KB} 14 August 2009
Psoriasis and Psoriatic Arthritis Alliance ^{PDF 79 KB} 14 August 2009
Royal College of Physicians ^{PDF 25 KB} 14 August 2009
Royal College of Nursing ^{PDF 21 KB} 14 August 2009
Department of Health ^{PDF 11 KB} 14 August 2009
Dorset PCT ^{PDF 25 KB} 14 August 2009
Welsh Assembly Government ^{PDF 27 KB} 14 August 2009
Abbott Laboratories ^{PDF 189 KB} 14 August 2009
Schering-Plough ^{PDF 30 KB} 14 August 2009
Wyeth Pharmaceutical ^{PDF 28 KB} 14 August 2009

Psoriasis - ustekinumab: appraisal consultation

Psoriasis - ustekinumab: appraisal consultation information
Psoriasis - ustekinumab: appraisal consultation document information
Psoriasis - ustekinumab: evaluation report
Psoriasis - ustekinumab: pre-meeting briefing ^{PDF 173 KB} 20 May 2009
Psoriasis - ustekinumab: Evidence Review Group report ^{PDF 1.48 MB} 20 May 2009
Psoriasis - ustekinumab: Non-manufacturer submissions
Psoriasis - ustekinumab: Non-manufacturer submissions - British Association of Dermatologists ^{PDF 53 KB} 20 May 2009
Psoriasis - ustekinumab: Non-manufacturer submissions - Dorset PCT ^{PDF 62 KB} 20 May 2009
Psoriasis - ustekinumab: Non-manufacturer submissions - The Psoriasis Association ^{PDF 49 KB} 20 May 2009
Psoriasis - ustekinumab: Non-manufacturer submissions - The Psoriasis and Psoriatic Arthritis Alliance ^{PDF 51 KB} 20 May 2009
Psoriasis - ustekinumab: Non-manufacturer submissions - The Royal College of Physicians ^{PDF 50 KB} 20 May 2009
Psoriasis - ustekinumab: Manufacturer submission
Psoriasis - ustekinumab: Manufacturer submission - Janssen-Cilag ^{PDF 2.52 MB} 20 May 2009
Psoriasis - ustekinumab: Manufacturer submission - NICE clarification letter ^{PDF 27 KB} 20 May 2009
Psoriasis - ustekinumab: Manufacturer submission - Manufacturer response to clarification letter ^{PDF 416 KB} 20 May 2009
Psoriasis - ustekinumab: Expert written personal statements
Psoriasis - ustekinumab: Expert written personal statements - Anstey information
Psoriasis - ustekinumab: Expert written personal statements - Anstey ^{PDF 20 KB} 20 May 2009
Psoriasis - ustekinumab: Expert written personal statements - Barker information
Psoriasis - ustekinumab: Expert written personal statements - Barker ^{PDF 21 KB} 20 May 2009
Psoriasis - ustekinumab: Expert written personal statements - Jobling information
Psoriasis - ustekinumab: Expert written personal statements - Jobling ^{PDF 20 KB} 20 May 2009
Psoriasis - ustekinumab: Expert written personal statements - McAteer information
Psoriasis - ustekinumab: Expert written personal statements - McAteer ^{PDF 20 KB} 20 May 2009

Psoriasis - ustekinumab: final scope

Psoriasis - ustekinumab: final scope ^{PDF 29 KB} 06 November 2008

Psoriasis - ustekinumab: stakeholder comments on the draft remit

Psoriasis - ustekinumab: stakeholder comments on the draft remit ^{PDF 106 KB} 06 November 2008

Psoriasis - ustekinumab: stakeholder comments on the provisional matrix of consultees and commentators

Psoriasis - ustekinumab: stakeholder comments on the provisional matrix of consultees and commentators ^{PDF 19 KB} 06 November 2008